Journal of Clinical Oncology
Articles in this Issue
Predictors of in-hospital mortality and palliative care utilization in metastatic renal cell carcinoma: A nationwide analysis of 2018–2022 U.S. hospitalizations.
e16567 Background: Despite transformative advances in systemic therapy, metastatic renal cell carcinoma (mRCC) remains ass...
Association of treatment-induced decrease of tumor chromosome Y and prognosis.
3136 Background: Loss of chromosome Y (LOY) in cancer has been linked to increased mortality. Since tumors that are not co...
Comparison of prognoses in pancreatic cancer patients receiving neoadjuvant therapy versus adjuvant therapy.
e16451 Background: Pancreatic cancer remains one of the most lethal malignancies, with limited long-term survival despite...
Safety and efficacy of CS2009, a first-in-class PD-1/VEGF/CTLA-4 trispecific antibody, in patients with advanced non-small cell lung cancer: Results from a phase 1/2 study.
8558 Background: CS2009 is a novel PD-1/VEGF/CTLA-4 trispecific antibody. An ongoing phase 1/2 study is evaluating its saf...
Longitudinal monitoring for post-surgical molecular residual disease in patients with stage I–IIIB melanoma using a whole-genome sequencing–based ctDNA assay.
9577 Background: Circulating tumor DNA (ctDNA) is a novel biomarker for detecting molecular residual disease (MRD) and mon...
The molecular landscape and clinical nomogram of pancreatic cancers harboring DNA damage repair genes alterations.
e16424 Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with 5-year survival below 13% an...
Circulating tumor DNA (ctDNA) as a biomarker for pathologic response and clinical outcomes in patients with cutaneous squamous cell carcinoma (CSCC) receiving neoadjuvant anti–PD-1 therapy.
9587 Background: ctDNA is a novel biomarker that can be used to evaluate recurrence and treatment response in multiple can...
Predicting multi-cancer risk from EHR data using multi-agent LLMs.
10501 Background: Accurate multi-cancer risk prediction is essential for optimizing screening strategies and yet remains c...
Cabozantinib plus nivolumab (C+N) versus sunitinib (S) in patients with advanced renal cell carcinoma (aRCC) and bone metastasis: Updated subgroup analysis of the phase 3 CheckMate-9ER trial.
4528 Background: In first-line aRCC, C+N significantly improved progression-free survival (PFS), overall survival (OS), an...
A phase I trial on the safety, tolerance, and preliminary efficacy of intracavitary injection of in situ vaccines (FOLactis) in patients with advanced solid tumors complicated with malignant pleural effusion.
2601 Background: Malignant pleural effusion (MPE) is caused by the metastasis of malignant tumors to the pleura. Tradition...
NoLEEta: No chemotherapy in intermediate-risk HR+ HER2− early breast cancer treated with ribociclib in the adjuvant setting—A non-inferiority phase III trial.
TPS645 Background: Historically, the treatment paradigm for hormone receptor-positive, HER2-negative early breast cancer (...
Dual HER2-targeted therapy with pyrotinib plus inetetamab and adebrelimab in previously treated HER2-amplified metastatic colorectal cancer: A prospective, single-arm, phase II clinical trial.
e15532 Background: Various approaches to HER2 inhibition have been explored for HER2-positive metastatic colorectal cancer...
Comparative effectiveness of antihypertensive drug classes in patients with gastrointestinal malignancy and incident hypertension.
e16359 Background: Over one-third of patients with cancer require antihypertensive therapy. Emerging evidence suggests ren...
Risk-stratified cancer screening in idiopathic inflammatory myopathies.
e23127 Background: Idiopathic inflammatory myopathies (IIM) are high-risk cancer cohorts with 20–25% peri-onset malignancy...
Tumor-specific supportive care utilization after first-line PD-1 inhibitor therapy: Real-world transfusion and mortality patterns in lung cancer and melanoma.
e20671 Background: Immune checkpoint inhibitors (ICIs) are standard first-line therapy for non–small cell lung cancer (NSC...
Comparative effectiveness of CAR-T and bispecific antibodies in relapsed/refractory large B-cell lymphoma: A network meta-analysis of phase III trials.
7090 Background: Second-line and later-line cellular therapies and bispecific antibodies have transformed the management o...
A personalized digital approach to cancer risk assessment in a diverse gynecology clinic.
e22642 Background: Most individuals who qualify for cancer genetic testing and enhanced breast cancer screening are not id...
Comparative efficacy of antifungal prophylaxis in acute myeloid leukemia: A systematic review and meta-analysis.
e18515 Background: Acute myeloid leukemia (AML) is characterized by prolonged neutropenia and a high risk of infections, i...
Analysis of sex-based differences in tumor microenvironments within hematopoietic and reticuloendothelial system malignancies.
7095 Background: While sex-specific disease incidence, genomic profiles, and survival outcomes are widely recognized in he...
Multi-omics approaches to unveil the mixed molecular characteristics of hepatoid adenocarcinoma of the stomach with neuroendocrine differentiation.
e16109 Background: Hepatoid adenocarcinoma of stomach with neuroendocrine differentiation (HAS-NEC) is an extremely rare s...
Baseline characteristics of a phase III randomized controlled trial of acupuncture for chemotherapy-induced peripheral neuropathy (ACT trial).
e24173 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common, painful, and disabling chemotherapy toxi...
Trends in sepsis-related mortality among adults with cancer aged ≥ 25 years in United States, 1999-2020: A CDC WONDER study.
e22600 Background: Sepsis is one of the leading causes of death worldwide, while mortality in patients with cancer and sep...
Do we really know how many veterans have cancer in the Veterans Health Administration?
e13745 Background: Veterans living in isolated and rural geographies often face barriers to timely specialty oncology care...
cfDNA WGS vs plasma proteomics for minimally invasive MRD assessment in multiple myeloma.
7546 Background: MRD assessment informs relapse risk in MM but is typically bone marrow-based and invasive. We therefore c...
PRTH-101: An investigational treatment for thoracic solid tumors targeting discoidin domain receptor (DDR1) and the tumor microenvironment (TME).
e20510 Background: Many tumors are resistant to existing targeted therapies and chemotherapies, with high treatment failur...